<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23201">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01677013</url>
  </required_header>
  <id_info>
    <org_study_id>PUACH-721002</org_study_id>
    <nct_id>NCT01677013</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Type 2 Diabetes Mellitus</brief_title>
  <official_title>Efficacy of Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Selective Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Aerospace Centre Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Aerospace Centre Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to evaluate the safety and efficiency of autologous bone marrow
      mononuclear cell transplantation in treating selective patients with type 2 Diabetes
      Mellitus. We hypothesized that autologous bone marrow stem cell transplantation would
      promote β-cells regeneration by directly differentiated from the transplanted BMMCs or
      stimulate local stem cells regeneration and thus decrease or eliminate the need of exogenous
      insulin and improve β-cells function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To study the safety and efficacy of bone marrow mononuclear cell transplantation in type 2
      diabetics. According to the intervention and baseline characteristics, patients are divided
      into 4 arms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>C-peptide</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction of medication</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Oral medication treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>type 2 diabetics with only oral medications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral medication plus BMMCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral medication plus insulin treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Type 2 diabetics who need insulin therapy with oral medications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral medication plus insulin plus BMMCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BMMCT</intervention_name>
    <description>Bone marrow mononuclear cell transplantation via selective catheterization</description>
    <arm_group_label>Oral medication plus BMMCT</arm_group_label>
    <arm_group_label>Oral medication plus insulin plus BMMCT</arm_group_label>
    <other_name>Bone marrow mononuclear cell transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  age 30-70

          -  stable doses of medication for at least 3 months

          -  BMI &lt;35 and &gt;18.5

        Exclusion Criteria:

          -  secondary cause for hyperglycemia

          -  pregnancy or nursing

          -  positive autoimmune antibody of diabetes

          -  severe complication or concurrent diseases

          -  active infection or febrile illness

          -  allergy to iodine

          -  history or signs of aortic aneurysm

          -  history or active pancreatic diseases

          -  known substance abuse or alcoholism or heavy smoking

          -  not suitable for other conditions upon investigators' expertise
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yizhong Wang, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuanjie Mao, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Biochemisty, National Cerebral and Cardiovascular Center; Department of Cardiology, China-Japan Friendship Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lei Lei, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danping Meng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiyang Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaolin Jia, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qiuming Jiang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yufang Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Song Dong, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liyan Yang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mingchao Ding, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liqin Cui, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bin Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xin Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Han Shi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Lei, M.D.</last_name>
    <phone>+86-10-59971870</phone>
    <email>leileihospital@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Hematology and Endocrinology, Peking University Aerospace Centre Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100049</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lei Lei, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 30, 2012</lastchanged_date>
  <firstreceived_date>August 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Aerospace Centre Hospital</investigator_affiliation>
    <investigator_full_name>Lei Lei, MD</investigator_full_name>
    <investigator_title>Endocrinologist</investigator_title>
  </responsible_party>
  <keyword>Type 2; diabetes mellitus; stem cell; safety; efficacy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
